Cancer-associated immunodefidency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

Journal of Clinical Investigation

Volumn 111, Issue 5, 2003, Pages 727-735

  Yang, Li ^a,b   Yamagata, Noboru ^a,b   Yadav, Rajwardhan ^a   Brandon, Suzanne ^a   Courtney, Regina L ^a   Morrow, Jason D ^a   Shyr, Yu ^a   Boothby, Mark ^a   Joyce, Sebastian ^a   Carbone, David P ^a,b   Breyer, Richard M ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN EP2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPH NODE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

ANIMALS; DENDRITIC CELLS; DINOPROSTONE; FEMALE; IMMUNOLOGIC DEFICIENCY SYNDROMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN E; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 85047687848     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16492     Document Type: Article

References (51)

1. Liu, C.H., et al. 2001. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276:18563-18569.
2. Williams, C.S., Tsujii, M., Reese, J., Dey, S.K., and DuBois, R.N. 2000. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:1589-1594.
3. Tsujii, M., et al. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:705-716.
4. Snijdewint, F.G., Kalinski, P., Wierenga, E.A., Bos, J.D., and Kapsenberg, M.L. 1993. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150:5321-5329.
5. Huang, M., et al. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1208-1216.
6. Stolina, M., et al. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:361-370.
7. Narumiya, S., Sugimoto, Y., and Ushikubi, F. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1193-1226.
8. Breyer, R.M., Bagdassarian, C.K., Myers, S.A., and Breyer, M.D. 2001. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41:661-690.
9. Tilley, S.L., Coffman, T.M., and Koller, B.H. 2001. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108:15-23. doi:10.1172/JCI200113416.
10. Fedyk, E.R., and Phipps, R.P. 1996. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc. Natl. Acad. Sci. U. S. A. 93:10978-10983.
11. Rocca, B., et al. 1999. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. Clin. Invest. 103:1469-1477.
12. Rocca, B., Spain, L.M., Ciabattoni, G., Patrono, C., and FitzGerald, G.A. 1999. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J. Immunol. 162:4589-4597.
13. 2 that regulate cellular immune responses in the mouse. J. Clin. Invest. 108:1229-1235. doi:10.1172/JCI200113640.
14. Strong, V.E., et al. 2001. Prostaglandin E2 receptors EP2 and EP4 are down-regulated in human mononuclear cells after injury. Surgery. 130:249-255.
15. Li, X., et al. 2000. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology. 141:2054-2061.
16. Harizi, H., Juzan, M., Grosset, C., Rashedi, M., and Gualde, N. 2001. Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol. 209:19-28.
17. Harizi, H., Juzan, M., Pitard, V., Moreau, J.F., and Gualde, N. 2002. Cyclooxygenase-2-issued prostaglandin E(2) enhances the production ofendogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168:2255-2263.
18. Rozic, J.G., Chakraborty, C., and Lala, P.K. 2001. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int. J. Cancer. 93:497-506.
19. Sonoshita, M., et al. 2001. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcDelta716 knockout mice. Nat. Med. 7:1048-1051.
20. Seno, H., et al. 2002. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62:506-511.
21. Kennedy, C.R., et al. 1999. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. 5:217-220.
22. Murphy, K.M., Heimberger, A.B., and Loh, D.Y. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science. 250:1720-1723.
23. Youn, J., et al. 1998. In vivo function of an interleukin 2 receptor beta chain (IL-2Rbeta)/IL-4Ralpha cytokine receptor chimera potentiates allergic airway disease. J. Exp. Med. 188:1803-1816.
24. DuBois, R.N., et al. 1994. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol. 266:G822-G827.
25. Song, H., et al. 2002. Cytosolic phospholipase A2alpha is crucial for 'ontime' embryo implantation that directs subsequent development. Development. 129:2879-2889.
26. Matti, H.J., et al. 2000. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156:965-976.
27. Mukutmoni, M., Hubbard, N.E., and Erickson, K.L. 2001. Prostaglandin E(2) modulation of vascular endothelial growth factor production in murine macrophages. Prostaglandins Leukot. Essent. Fatty Acids. 65:123-131.
28. Rodolfo, M., et al. 1994. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. Int. J. Cancer. 57:440-447.
29. Griswold, D., and Corbett, T. 1975. A colon tumor model for anticancer agent evaluation. Cancer. 36:2441-2444.
30. Gagandeep, S., et al. 1996. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 3:83-88.
31. Hida, T., et al. 1998. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:3761-3764.
32. Eberhart, C.E., et al. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1183-1188.
33. Sano, H., et al. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:3785-3789.
34. Kargman, S.L., et al. 1995. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:2556-2559.
35. Chen, Y., and Hughes-Fulford, M. 2000. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br. J. Cancer. 82:2000-2006.
36. Chen, W.S., et al. 2001. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer. 91:894-899.
37. Berens, M.E., Salmon, S.E., and Davis, T.P. 1984. Quantitative analysis of prostaglandins in cell culture medium by high-resolution gas chromatography with electron-capture detection. J. Chromatogr. 307:251-260.
38. Oshima, M., et al. 1996. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:803-809.
39. Keith, R.L., et al. 2002. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 62:734-740.
40. Kalinski, P., Hilkens, C.M., Snijders, A., Snijdewint, F.G., and Kapsenberg, M.L. 1997. Dendritic cells, obtained from peripheral blood precursors in the presence of PGE2, promote Th2 responses. Adv. Exp. Med. Biol. 417:363-367.
41. Kalinski, P., Hilkens, C.M., Snijders, A., Snijdewint, F.G., and Kapsenberg, M.L. 1997. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159:28-35.
42. Gabrilovich, D.I., et al. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendricic cells. Nat. Med. 2:1096-1103.
43. Gabrilovich, D.I., Ciernik, I.F., and Carbone, D.P. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:101-110.
44. Carbone, F.R., Kurts, C., Bennett, S.R., Miller, J.F., and Heath, W.R. 1998. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today. 19:368-373.
45. Huang, A.Y. 1994. Role ofbone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:961-965.
46. Yewdell, J.W., Norbury, C.C., and Bennink, J.R. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1-77.
47. Jeannin, P., et al. 2000. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 1:502-509.
48. Ossendorp, F., Mengede, E., Camps, M., Filius, R., and Melief, C.J. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693-702.
49. Baxevanis, C.N., et al. 2000. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 164:3902-3912.
50. Luo, J.S., Kammerer, R., and von Kleist, S. 2000. Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion. Tumour Biol. 21:11-20.
51. Cheng, X., and Lopez, D.M. 1998. CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine. J. Immunol. 160:2735-2741.